RxDoctor Payments Data

George Okafor, MD

Internal Medicine · Conyers, GANPI 1710909817

Payments from drug & device makers

$2,001in general payments, 2019–2025

Across 91 payments — averaging $21.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$298
  • Abbott$273
  • Amgen$263
  • Boehringer Ingelheim$255
  • Johnson & Johnson$199
  • AstraZeneca$170
  • plus $544 from 11 others

What the payments were for

  • Food & beverage$1,94297%
  • Gifts$593%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,001 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$113,650
Medicare patients
99
Services billed
1,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin54$83,289
FarxigaDapagliflozin Propanediol38$49,433
EliquisApixaban18$23,220
XareltoRivaroxaban31$22,977
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$20,165
Synjardy XrEmpagliflozin/Metformin Hcl32$19,834
OzempicSemaglutide17$18,043
JanumetSitagliptin Phos/Metformin Hcl12$9,629
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$6,733
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$3,397
Atorvastatin Calcium384$3,206
Nifedipine ErNifedipine105$2,752
Rosuvastatin Calcium182$1,981
Diclofenac Sodium54$1,572
Ezetimibe71$1,510

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$255$103,12386 claims
AstraZenecaFarxiga$170$49,43338 claims
PfizerEliquis$39$23,22018 claims
Johnson & JohnsonXarelto$199$22,97731 claims
GSKTrelegy Ellipta$76$20,16532 claims
Novo NordiskOzempic$87$18,04317 claims
MerckJanumet$57$9,62912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Conyers

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →